morphine

(redirected from Avinza)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for morphine

an alkaloid narcotic drug extracted from opium

References in periodicals archive ?
Brand name Controlled-release contents Avinza Oral morphine Duragesic Transdermal fentanyl Embeda Oral morphine and naltrexone Exalgo Oral hydromorphone Kadian Oral morphine Morphine sulfate contin Oral morphine Opana extended release Oral oxymorphone Oramorph sustained release Oral morphine Ultram extended release Oral tramadol Brand name Frequency taken/changed Avinza One a day Duragesic Every three days [topical] Embeda One or two a day Exalgo One a day Kadian One or two a day Morphine sulfate contin Two or three a day Opana extended release Two a day Oramorph sustained release Two or three a day Ultram extended release One a day Table 2.
Under the terms of an agreement announced in 2004, manufacturing of AVINZA will commence for a five-year term.
As part of the deal with Ligand, Elan will forego its option to negotiate a co-promotion agreement with Ligand for the Avinza drug in the United States and Canada, but continue to manufacture the product at a US facility.
Ligand may also have indemnification obligations to King Pharmaceuticals or Eisai in connection with the sales of the Avinza and oncology product lines.
In the randomized, double-blind study, 295 people with osreoarthritis pain received 30 mg of extended-release morphine sulfate (Avinza) in the morning, 30 mg of Avinza in the evening, MS Contin (morphine) 15 mg twice daily, or placebo.
In the randomized, double-blind study, 295 people with osteoarthritis pain received 30 mg of extended-release morphine sulfate (Avinza) in the morning, 30 mg of Avinza in the evening, MS Contin (morphine) 15 mg twice daily or placebo.
TROUBLED Irish pharmaceutical company Elan was celebrating yesterday after confirming it had won approval from the US Food and Drug Administration for its Avinza chronic pain treatment.
Ligand may also have indemnification obligations to Pfizer or Eisai in connection with the sales of the Avinza and oncology product lines.
Ligand may also have indemnification obligations to King Pharmaceuticals or Eisai in connection with the sales of the Avinza and oncology product lines and may be subject to future tax liabilities which are larger than the provision for income taxes reflected in Ligand's 2010 year-end financial statements.